Abstract
TNBC refers to breast cancer patients with negative estrogen receptor ER, PR and HER-2. It accounts for about 1520% of all breast cancer cases and has a higher rate of disease recurrence and a worse prognosis than other breast cancer subtypes. Chemotherapy is the most effective treatment now available for TNBC, but it has major adverse consequences on human health. Therefore, the development of new TNBC treatment strategies has become an urgent clinical need. This article first starts with the different subtypes of TNBC, analyzes and summarizes the pathogenesis of TNBC and recent research progress. Secondly, the potential targets of TNBC and the development of targeted treatments based on these targets are analyzed. Finally, it is concluded that it is easier to achieve curative effect by using appropriate specific treatments for different subtypes of TNBC. By summarizing existing treatment regimens and their applicable TNBC subtypes, this article aims to provide new insights for follow-up treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
